Wednesday, 2 November 2011

BRAVO - Oral laquinimod fails to reduce risk of relapse but delays MS progression

Source MS Trust:
Results from the BRAVO trial, a phase III double blind placebo controlled study comparing 0.6mg of laquinimod with interferon beta 1a and placebo over two years in people with relapsing remitting MS, found no reduction in relapse risk. The study included 1,331 people with relapsing remitting MS and is the second of two global phase III trials.  For more click here.